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(http://cjournal homepage: www.elsevier.com/locate/joaEditorialMolecular genetics have opened a new era for arrhythmia research, but also
Pandora's box?Our so-called fate is largely ordained by our ancestors, not by
the stars.
…Pandora regretted opening her box.
In “The Island” by Victoria Hislop (British novelist).
The Japanese Heart Rhythm Society and the Asia Paciﬁc Heart
Rhythm Society have jointly produced a series of review and ori-
ginal articles on up-to-date themes in heart rhythm research. This
special issue will focus on “genes and arrhythmias”, which are
currently in the spotlight as a novel ﬁeld of cardiovascular medi-
cine. Scientiﬁc progress in genetics prompted the discovery of new
genes responsible for heart diseases and elucidated their speciﬁc
molecular mechanisms of pathogenicity. For example, variants of
genes encoding a variety of ion channels or their associated pro-
teins were found to cause inherited arrhythmias, such as long QT
syndrome, Brugada syndrome, catecholaminergic polymorphic
ventricular tachycardia, progressive cardiac conduction defect, and
short QT syndrome. Thanks to functional analysis by using elec-
trophysiological methods, the precise mechanisms underlying
their respective pathogenicity have been fully proven, even by
employing cardiomyocytes differentiated from patient-speciﬁc iPS
cells. Rapid adoption and spread of genetic tests for these diseases
have offered us a unique approach, not only for diagnosis, but also
for risk assessment and therapeutic decisions, and eventually for
personalized medicine. Notably because the list of inherited
arrhythmias is still expanding.x.doi.org/10.1016/j.joa.2016.07.001
76/& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access a
reativecommons.org/licenses/by-nc-nd/4.0/).According to our rapidly developing knowledge on these
inherited arrhythmias, several key guidelines are now available in
regard to genetic testing, diagnosis, and treatment [1–5]. Though
these publications cover important recommendations, we still
need some details for the diagnosis and therapy of this new dis-
ease category, especially after the advent of high-output sequen-
cing techniques using next generation sequencers, because we
would identify too many variants from both patients and healthy
individuals. It is of extreme clinical importance to distinguish
between pathogenic variants and those of uncertain signiﬁcance
(i.e., VUSs). Additionally, these variants include a number of single
nucleotide polymorphisms (SNPs), and the distribution of SNPsrticle under the CC BY-NC-ND license
Editorial / Journal of Arrhythmia 32 (2016) 313–314314differs considerably depending on ethnic group. Therefore,
ethnicity-speciﬁc SNP databases are required to make a decision
whether a variant detected in a patient family is signiﬁcant or not.
Now that we have opened a door to modern molecular genetics
(or Pandora's box) as a new technology, it is deﬁnitely up to us to
manage it in an appropriate way (excluding VUSs). The importance
of making an accurate diagnosis prior to genetic testing is now
more necessary than before. Therefore, this issue of Journal of
Arrhythmia highlights the articles from the invited experts in this
ﬁeld, especially from the Asia Paciﬁc region, to describe and
review their most specialized research themes regarding “genes
and arrhythmias”. The editors believe that this state-of-art cover-
age will be useful for understanding the new era in genes and
arrhythmias.Conﬂict of interest
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